CoChat

Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease

Open access
Swerdlow, Russell H. · 2018 · Journal of Alzheimer’s Disease

The DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.

Abstract

Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-170585

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Secondary mitochondrial cascade. Secondary mitochondrial cascades are compatible with the amyloid cascade hypothesis, and could mediate Aβ toxicity. As illustrated, Aβ can directly introduce various AD-associated functional changes and pathologies, and directly or indirectly cause mitochondrial dysfunction. Aβ-induced mitochondrial dysfunction, in turn, could further contribute to or initiate additional AD-associated functional changes and pathologies.
Fig.1 Secondary mitochondrial cascade. Secondary mitochondrial cascades are compatible with the amyloid cascade hypothesis, and could mediate Aβ toxicity. As illustrated, Aβ can directly introduce various AD-associated functional changes and pathologies, and directly or indirectly cause mitochondrial dysfunction. Aβ-induced mitochondrial dysfunction, in turn, could further contribute to or initiate additional AD-associated functional changes and pathologies.CC BY-NC · PubMed Central
Fig.2 Primary mitochondrial cascade. A primary mitochondrial cascade is incompatible with the amyloid cascade hypothesis. Under this scenario, impaired mitochondrial function and associated bioenergetic changes alter Aβ homeostasis and lead to an accumulation of Aβ. Aβ may or may not in turn contribute to the development of other AD-associated functional changes and pathologies.
Fig.2 Primary mitochondrial cascade. A primary mitochondrial cascade is incompatible with the amyloid cascade hypothesis. Under this scenario, impaired mitochondrial function and associated bioenergetic changes alter Aβ homeostasis and lead to an accumulation of Aβ. Aβ may or may not in turn contribute to the development of other AD-associated functional changes and pathologies.CC BY-NC · PubMed Central
Fig.3 Could mitochondrial function influence recognized AD biomarker changes? Studies that track dynamic biomarker shifts suggest changes in Aβ (lower CSF levels or plaque accumulation) precede tau changes (lower CSF tau or tangle accumulation beyond the medial temporal regions). Reductions in brain volume (hippocampal volumes) follow Aβ and tau changes. Declining memory abilities and dementia eventually occur. Additional data, though, suggest metabolism-relevant characteristics may distinguish high AD risk individual from low AD risk individuals before detectable Aβ changes occur. Mitochondrial function also changes with advancing age. It is reasonable to consider whether mitochondria define thresholds at which these biomarker changes begin to manifest.
Fig.3 Could mitochondrial function influence recognized AD biomarker changes? Studies that track dynamic biomarker shifts suggest changes in Aβ (lower CSF levels or plaque accumulation) precede tau changes (lower CSF tau or tangle accumulation beyond the medial temporal regions). Reductions in brain volume (hippocampal volumes) follow Aβ and tau changes. Declining memory abilities and dementia eventually occur. Additional data, though, suggest metabolism-relevant characteristics may distinguish high AD risk individual from low AD risk individuals before detectable Aβ changes occur. Mitochondrial function also changes with advancing age. It is reasonable to consider whether mitochondria define thresholds at which these biomarker changes begin to manifest.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 7

  1. de Leon MJ, 1983, AJNR Am J Neuroradiol, 4, 568
  2. Fukuyama H, 1994, J Nucl Med, 35, 1
  3. Fernandez-Vizarra P, 2004, Histol Histopathol, 19, 823
  4. Zhu X, 2013, J Alzheimers Dis, 33, S253
  5. Askanas V, 1992, Am J Pathol, 141, 31
  6. 10.1002/1531-8249(200008)48:2<148::AID-ANA3>3.0.CO;2-7 · doi:10.1002/1531-8249(200008)48:2<148::aid-ana3>3.0.co;2-7
  7. Parker WD, 1990, Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease

Cited by

See all 856

Metadata

Authors
Swerdlow, R. H.
Affiliations
University of Kansas (US)
Corresponding author
Swerdlow, Russell H.
Venue
Journal of Alzheimer’s Disease
Published
2017-10-07
Volume
62
Issue
3
Pages
1403-1416
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2764071986
Cited by
850
References
154
Citations by year
2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
FWCI
5.84
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (P30AG035982)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, mitochondrial dysfunction
MeSH terms
Alzheimer Disease, Animals, Humans, Mitochondria

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.